Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Role of the TAP63 isoform in recurrent nasal polyps

A. Terrinoni, R. Palombo, C. Pitolli, S. Caporali, R. De Berardinis, S. Ciccarone, A. Lanzillotta, S. Mauramati, G. Porta, M. Minieri, G. Melino, S. Bernardini, E. Bruno

. 2019 ; 65 (4) : 170-180.

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20010294

The pathogenic molecular mechanisms underlying the insurgence of nasal polyps has not been completely defined. In some patients, these lesions can have a recurrence after surgery removal, and the difference between recurrent and not recurrent patients is still unclear. To molecularly characterize and distinguish between these two classes, a cohort of patients affected by nasal polyposis was analysed. In all patients we analysed the p63 isoform expression using fresh tissues taken after surgery. Moreover, confocal immunofluorescence analysis of fixed sections was performed. The results show high ΔNp63 expression in samples from the nasal polyps of patients compared to the normal epithelia. Analysis of the expression level of the TAp63 isoform shows differential expression between the patients with recurrence compared to those not recurring. The data, considered as the ΔN/TAp63 ratio, really discriminate the two groups. In fact, even though ΔNp63 is expressed in non-recurrent patients, the resulting ratio ΔN/TAp63 is significantly lower in these patients. This clearly indicates that the status of TAp63 expression, represented by the ΔN/TAp63 ratio, could be considered a prognostic marker of low recurrence probability. In these samples we also investigated the expression of OTX2 transcription factor, known to be a selective activator of TAp63, detecting a significant correlation. Database analysis of HNSCC patients showed increased survival for the patients presenting OTX2 amplification and/or overexpression. These results, together with the fact that TAp63 can be selectively upregulated by HDAC inhibitors, open the possibility to consider local treatment of recurrent nasal polyps with these molecules.

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc20010294
003      
CZ-PrNML
005      
20200721125336.0
007      
ta
008      
200707s2019 xr ad f 000 0|eng||
009      
AR
035    __
$a (PubMed)31903890
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Terrinoni, A. $u Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
245    10
$a Role of the TAP63 isoform in recurrent nasal polyps / $c A. Terrinoni, R. Palombo, C. Pitolli, S. Caporali, R. De Berardinis, S. Ciccarone, A. Lanzillotta, S. Mauramati, G. Porta, M. Minieri, G. Melino, S. Bernardini, E. Bruno
504    __
$a Literatura
520    9_
$a The pathogenic molecular mechanisms underlying the insurgence of nasal polyps has not been completely defined. In some patients, these lesions can have a recurrence after surgery removal, and the difference between recurrent and not recurrent patients is still unclear. To molecularly characterize and distinguish between these two classes, a cohort of patients affected by nasal polyposis was analysed. In all patients we analysed the p63 isoform expression using fresh tissues taken after surgery. Moreover, confocal immunofluorescence analysis of fixed sections was performed. The results show high ΔNp63 expression in samples from the nasal polyps of patients compared to the normal epithelia. Analysis of the expression level of the TAp63 isoform shows differential expression between the patients with recurrence compared to those not recurring. The data, considered as the ΔN/TAp63 ratio, really discriminate the two groups. In fact, even though ΔNp63 is expressed in non-recurrent patients, the resulting ratio ΔN/TAp63 is significantly lower in these patients. This clearly indicates that the status of TAp63 expression, represented by the ΔN/TAp63 ratio, could be considered a prognostic marker of low recurrence probability. In these samples we also investigated the expression of OTX2 transcription factor, known to be a selective activator of TAp63, detecting a significant correlation. Database analysis of HNSCC patients showed increased survival for the patients presenting OTX2 amplification and/or overexpression. These results, together with the fact that TAp63 can be selectively upregulated by HDAC inhibitors, open the possibility to consider local treatment of recurrent nasal polyps with these molecules.
650    _2
$a fluorescenční protilátková technika $7 D005455
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a nosní polypy $x genetika $x metabolismus $7 D009298
650    _2
$a transkripční faktory Otx $x genetika $x metabolismus $7 D051857
650    _2
$a protein - isoformy $x genetika $x metabolismus $7 D020033
650    _2
$a transkripční faktory $x genetika $x metabolismus $7 D014157
650    _2
$a nádorové supresorové proteiny $x genetika $x metabolismus $7 D025521
655    _2
$a časopisecké články $7 D016428
700    1_
$a Palombo, R. $u Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
700    1_
$a Pitolli, C. $u Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Rome, Italy
700    1_
$a Caporali, S. $u Department of Industrial Engineering, University of Rome Tor Vergata, Rome, Italy
700    1_
$a De Berardinis, R. $u Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Rome, Italy
700    1_
$a Ciccarone, S. $u Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Rome, Italy
700    1_
$a Lanzillotta, A. $u Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Rome, Italy
700    1_
$a Mauramati, S. $u University of Pavia, Italy and Department of Otorhinolaryngology, University of Pavia, Foundation IRCCS Policlinico "San Matteo", Pavia, Italy
700    1_
$a Porta, G. $u Department of Medicine and Surgery, University of Insubria, Varese, Italy
700    1_
$a Minieri, M. $u Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
700    1_
$a Melino, G. $u Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
700    1_
$a Bernardini, S. $u Department of Industrial Engineering, University of Rome Tor Vergata, Rome, Italy
700    1_
$a Bruno, E. $u Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Rome, Italy
773    0_
$w MED00011004 $t Folia biologica $x 0015-5500 $g Roč. 65, č. 4 (2019), s. 170-180
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31903890 $y Pubmed
856    41
$u https://fb.cuni.cz/file/5902/fb2019a0017.pdf $y plný text volně přístupný
910    __
$a ABA008 $b A 970 $c 89 $y p $z 0
990    __
$a 20200707 $b ABA008
991    __
$a 20200710132211 $b ABA008
999    __
$a ok $b bmc $g 1546289 $s 1100386
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 65 $c 4 $d 170-180 $i 0015-5500 $m Folia biologica (Praha) $n Folia biol. (Praha) $x MED00011004
LZP    __
$b NLK118 $a Pubmed-20200707

Najít záznam

Citační ukazatele

Možnosti archivace